摘要
目的探讨肥胖型和非肥胖型多囊卵巢综合征(PCOS)患者的临床代谢特征。方法根据体质量指数(BMI)的测定结果,将94例PCOS患者分为肥胖组(BMI≥25)36例和非肥胖组(BMI<25)58例。对2组患者早卵泡期或闭经状态(子宫内膜≤5 mm)下各项性激素,各时点的血糖、胰岛素水平、胰岛素抵抗指数(HOMA IR)进行比较。结果①2组患者卵泡刺激素(FSH)、血清泌乳素(PRL)水平比较差异无统计学意义(P>0.05);肥胖组的睾酮(T)水平高于非肥胖组,黄体生成素(LH)水平低于非肥胖组(P<0.05或P<0.01)。②肥胖组糖负荷后血糖、胰岛素水平及HOMA IR均高于非肥胖组(P<0.05或P<0.01)。③肥胖组胰岛素抵抗发生率为44.4%,非肥胖组胰岛素抵抗发生率为13.8%,2组比较差异有统计学意义(χ2=3.994,P<0.05)。结论 PCOS患者存在个体差异性,根据体质量的不同其激素水平改变不同,肥胖者以T水平升高为主,同时多伴有不同程度的胰岛素抵抗;非肥胖者则以LH升高为主要变化。
Objective To study the metabolic features of obese and nonobese women with ovary synthesis symptoms.Methods According to survey the body weight index(BMI),screen 94 PCOS patients' examples to divide into two groups-36 obese group(BMI≥25) examples and 58 non-obese group(BMI25) examples.Compare two group patients' each sex hormone,blood sugar level,the insulin level of each time and stable state model insulin's resistance index(HOMAIR) in early follicle period or the menopause condition(endometrium ≤5 mm).Results ①The comparison of the obese group and the nonobese group PCOS patients' internal secretion hormone level,the differenciation between the level of FSH and PRL hormone had no significant(P0.05),T level is higher than the nonobese group,LH level is lower than the nonobese group(P0.05 or P0.01).②After the sugar load of the obese group,the blood sugar level、insulin level and HOMA IR are higher than the non-obese group(P0.05 or P0.01).③The obese group insulin resistant rate is 44.4%,but the nonobese group insulin resistant rate is 13.8%,the difference of two group PCOS patients' insulin resistant rate has statistics significance(χ2=3.994,P0.05).Conclusion The women with ovary synthesis symptoms have the individual difference,according to the different body weight its hormone level change is different,the obesity go up mainly in T level,meanwhile there are accompanied by the various degree's insulin resistance,the nonobesity go up mainly in LH level.
出处
《南昌大学学报(医学版)》
CAS
2010年第7期55-57,共3页
Journal of Nanchang University:Medical Sciences
关键词
多囊卵巢综合征
肥胖
性激素
胰岛素抵抗
polycystic ovary syndrome
obesity
sex hormone
insulin resistance